Abstract
BackgroundTimely detection of treatment failure with subsequent switch to second-line regimen reduces mortality among HIV infected people on antiretroviral therapy (ART). This paper aims to investigate the detection of immunological treatment failure and switch rate to second line regimen in Ethiopia.MethodsA retrospective cohort study was conducted among HIV infected patients (age > 15 years) who initiated ART between 2007 and 2009. The required data were collected from patient registers and formats. Data were entered and validated using EpiData software and then exported to SPSS version 20.0 for analysis. Odds ratio with 95 % CI was used to assess whether immunological treatment failure was associated with experiencing unfavorable treatment outcomes (death or lost to follow up).ResultsRecords of 293 patients were reviewed with a total of 1545 Person-Years of Observation (PYO). The median baseline CD4 count was 115 cells/mm3 (IQR: 64–176). A total of 46 (15.7 %) patients experienced immunological treatment failure. The immunological failure rate was 3.0 per 100 PYO. Treatment was switched to second-line regimen for six (2.1 %) patients. The rate of treatment switch to second-line regimen for any purpose was 0.4 per 100 PYO. Out of the six patients, only two fulfilled the WHO criteria for immunological failure; the remaining four patients had their treatment switched to second-line regimen for other purposes. This implies that only 4.3 % (2/46) of patients with immunological failure were switched to second-line regimen. The risk of experiencing unfavorable outcome was 5.75 (95 % CI 1.11, 29.8) times higher among those who had immunological failure than their counterparts after adjusting for baseline CD4 count.ConclusionsMajority of patients with immunological treatment failures were not detected and continued taking the failed regimen. Further studies are required to assess and explore why patients with immunological failure are not switched to second-line regimen as per the standard protocol.
Highlights
Detection of treatment failure with subsequent switch to second-line regimen reduces mortality among HIV infected people on antiretroviral therapy (ART)
12.9 million people living with HIV were receiving antiretroviral therapy (ART) globally, out of which 11.7 million were in low and middle-income countries representing 36 % of the 32.6 million people living with the virus in low and middle-income countries [1]
The definitions of Teshome and Tefera BMC Immunology (2015) 16:55 immunological failure are either fall of CD4 count to baseline or 50 % fall from on-treatment peak value or persistent CD4 levels below 100 cells/mm3 [3]
Summary
Detection of treatment failure with subsequent switch to second-line regimen reduces mortality among HIV infected people on antiretroviral therapy (ART). This paper aims to investigate the detection of immunological treatment failure and switch rate to second line regimen in Ethiopia. 12.9 million people living with HIV were receiving antiretroviral therapy (ART) globally, out of which 11.7 million were in low and middle-income countries representing 36 % of the 32.6 million people living with the virus in low and middle-income countries [1]. As the ART uptake increases, the emergence of resistant viruses resulting in treatment failure is inevitable and should be anticipated proactively. The diagnosis of treatment failure is guided by viral load testing in high income countries; this is not the case in most low income countries because viral load testing is costly and requires advanced infrastructures [2, 3]. The definitions of Teshome and Tefera BMC Immunology (2015) 16:55 immunological failure are either fall of CD4 count to baseline (or below) or 50 % fall from on-treatment peak value or persistent CD4 levels below 100 cells/mm3 [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
